Beta-2 Glycoprotein-1, Apolipoprotein-H Antibodies
Affinity Biologicals, Inc. manufactures a broad range of Beta-2 Glycoprotein-1, Apolipoprotein-H Antibodies which can be found in the listing below. Further information about each individual Beta-2 Glycoprotein-1, Apolipoprotein-H Antibody is available by following the associated links. Our Beta-2 Glycoprotein-1, Apolipoprotein-H Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays. These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins. Affinity’s Beta-2 Glycoprotein-1, Apolipoprotein-H Antibodies are manufactured for use in research applications.
Listing of Beta-2 Glycoprotein-1, Apolipoprotein-H Antibodies
GAB2G-IG – Goat anti human beta-2-glycoprotein-1 (APO-H), purified IgG (5mg vial)
GAB2G-HRP – Goat anti human b2-Glycoprotein-1 (APO-H), peroxidase conjugated IgG (0.2 mg vial)
GAB2G-AP – Goat anti human b2-Glycoprotein-1 (APO-H), affinity purified IgG (0.5 mg vial)
APOH-EIA – Apolipoprotein-H (Beta-2-Glycoprotein-1) Paired Antibody Set – 5 plate set
Description of Beta-2-Glycoprotein-1 (Apolipoprotein-H, APOH)
Beta-2-Glycoprotein 1 (B2GP1), also known as Apolipoprotein-H (APOH), is a plasma glycoprotein that circulates at a concentration of 200 ug/ml (4 μM). Synthesized in the liver, β2GP1 is a single chain molecule of 48 kDa, consisting of five repeating internally disulphide-bonded structures referred to as sushi domains. Relative to other glycoproteins, β2GP1 has an unusually high content of cysteine (6.2%), proline (8.3%) and carbohydrate (19%). Almost half the circulating β2GP1 in plasma is associated with lipoproteins of all major fractions. β2GP1 has been demonstrated to bind negatively charged phospholipids, heparin and platelets. Although the precise function(s) are as yet unknown, β2GP1 has been demonstrated to interfere with blood coagulation by competitively binding to negatively charged phospholipid surfaces exposed during cell activation or damage. Recent evidence also implicates β2GP1 as a cofactor recognized by anti-phospholipid antibodies present in some autoimmune disorders such as systemic lupus erythematosus (SLE)1-3.
References and Reviews
- Lee, NS, Brewer HB Jr., Osborne JC Jr.; β2Glycoprotein I: Molecular Properties of an Unusual Apolipoprotein, Apolipoprotein H; JBC 258, pp 4765-4770, 1983.
- Schousboe I; β2Glycoprotein I: A Plasma Inhibitor of the Contact Activation of the Intrinsic Blood Coagulation Pathway. Blood 66, pp 1086-1091, 1985.
- Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA; Prothrombinase activity of human platelets is inhibited by β2Glycoprotein I; Biochimica et Biophysica Acta 884, pp 142-149, 1986.